Merck stock edges higher as Keytruda drives double digit growth

Merck stock continues to reflect strong demand for oncology and vaccines, with Keytruda and Gardasil lifting recent quarterly revenue and earnings while investors watch upcoming data and patent timelines.

Merck stock, tied to Merck & Co., Inc. (ISIN US58933Y1055) and traded on the New York Stock Exchange, has been supported by brisk demand for its oncology and vaccines portfolio, with the latest reported quarter showing double digit top line growth and rising earnings per share according to company disclosures for Q1 2025.

In that Q1 2025 period, Merck reported total revenue of around $16 billion, up roughly 9% year over year from about $14.7 billion in Q1 2024, reflecting strong contributions from its flagship cancer drug Keytruda and HPV vaccine Gardasil in line with the company’s investor communications.

The same Q1 2025 update indicated that Merck’s adjusted earnings per share came in near $2.20, compared with approximately $1.96 a year earlier, underscoring that profit growth continued to outpace revenue as the product mix shifted toward higher margin immuno-oncology and vaccines.

Revenue up about 9 percent

Merck’s revenue expansion in Q1 2025 of close to 9% versus Q1 2024 was driven primarily by oncology, where Keytruda sales reached an estimated $7.3 billion for the quarter compared with roughly $6.6 billion a year earlier, representing around 11% growth as outlined in the company’s recent filings and presentations.

Vaccines contributed a second pillar, with Gardasil and Gardasil 9 combined sales in Q1 2025 reported at about $2.2 billion versus some $2.0 billion in Q1 2024, an increase of near 10% that management attributed to continued uptake in both established markets and selected international regions.

Beyond these headline franchises, Merck’s hospital acute care and animal health businesses added incremental growth, keeping total revenue momentum intact even as certain legacy products faced more competitive pressure and gradual declines as noted in prior quarterly discussions.

Keytruda and Gardasil shape margin profile

For investors following Merck stock, the margin profile matters because Keytruda and Gardasil tend to carry higher profitability than older primary care drugs, and Merck’s Q1 2025 results indicated that non-GAAP operating margin edged higher relative to Q1 2024 in tandem with the revenue mix shift toward oncology and vaccines.

Management has repeatedly highlighted the scale of the Keytruda franchise, with annualized sales now comfortably above $25 billion based on recent trailing twelve month figures, making it one of the largest single drug revenue contributors globally and a key determinant of Merck’s valuation in the S&P 500 health care cohort.

At the same time, Gardasil’s growth has supported Merck’s vaccines segment, where annual revenue has been trending in the low double digit range year over year, helping to diversify cash flows across immuno-oncology and preventive therapies despite seasonal patterns that can affect individual quarters.

Keytruda cancer therapy backbone

Keytruda, Merck’s programmed death receptor-1 (PD-1) blocking antibody, has become a backbone therapy across multiple cancer indications, including non-small cell lung cancer, melanoma, and certain head and neck cancers, with its revenue growth in Q1 2025 near 11% versus Q1 2024 underscoring continuing clinical and commercial traction.

The drug’s label now spans dozens of approved indications worldwide, and Merck continues to invest heavily in trials evaluating Keytruda in earlier lines of therapy and in combination regimens, seeking to sustain growth even as patent expiries are expected later in the decade.

From a cash flow perspective, Keytruda’s scale provides Merck with resources to fund acquisitions, partnerships, and internal research programs, while also supporting its dividend policy that has included regular annual increases in recent years and a payout ratio aligned with peers in the large cap pharmaceutical space.

Gardasil vaccine supports long term prevention

Gardasil and Gardasil 9, Merck’s human papillomavirus (HPV) vaccines, contribute meaningfully to the company’s public health footprint and financial results, with Q1 2025 revenue of about $2.2 billion compared with roughly $2.0 billion a year earlier, highlighting sustained demand for HPV prevention programs.

Merck has cited broadening age range recommendations and geographic expansion as drivers for Gardasil uptake, with particular growth contributions from select Asian and European markets where immunization programs continue to expand.

The vaccines portfolio also includes products targeting other infectious diseases, and the mix of preventive and therapeutic offerings gives Merck a diversified revenue base that can smooth trends across economic and reimbursement cycles.

Pipeline and patent timeline frame valuation

Looking beyond current quarter metrics, Merck’s pipeline strategy and intellectual property timeline shape expectations for Merck stock over the medium term, as investors weigh potential biosimilar competition to Keytruda later in the decade against the emergence of new oncology, immunology, and cardiometabolic assets.

Merck has emphasized so called next wave therapies in areas such as antibody-drug conjugates, RNA based approaches, and cardiovascular disease, seeking to bring forward candidates that can contribute meaningful revenue before and after key patent cliffs.

Recent development updates have highlighted early stage data in certain oncology programs and cardiometabolic targets, although most of these candidates remain several years away from potential commercial contribution, underscoring the importance of continued Keytruda and Gardasil performance in the near term.

Dividend policy and balance sheet

Merck’s capital allocation framework continues to balance research investment, shareholder returns, and strategic transactions, with the company maintaining a sizable dividend that has grown steadily over time in line with its earnings trajectory.

In recent reporting periods, Merck has also noted a disciplined approach to leverage, keeping net debt at levels that support investment grade credit ratings, which helps to keep funding costs manageable for pipeline development and potential bolt on acquisitions.

Share repurchases have been used opportunistically, complementing the dividend while leaving scope for cash deployment into clinical programs and licensing deals that strengthen the long term portfolio.

Merck & Co. product focus

Beyond Keytruda and Gardasil, Merck’s portfolio spans hospital acute care, diabetes, and animal health, but the oncology and vaccines franchises now account for a large portion of total revenue, giving investors a relatively clear lens on the drivers that matter most for Merck stock.

Animal health has offered steady growth through products for companion animals and livestock, while hospital acute care medicines provide essential therapeutic options for serious conditions encountered in inpatient settings.

This blend of specialty and broader care offerings, combined with Merck’s global commercial footprint, allows the company to participate in a wide range of health care spending streams and potentially offset regional volatility in any single market.

Merck stock and recent market context

Merck stock, listed on the NYSE under the ticker MRK, trades as part of the S&P 500 health care sector and tends to be followed closely by institutional and retail investors seeking exposure to large cap pharmaceuticals and oncology driven growth.

In recent months, the share price has reflected both optimism around Keytruda and Gardasil and caution about eventual patent expiries, with valuation levels influenced by how long investors expect Merck to sustain double digit oncology revenue growth and robust vaccines performance.

Market capitalization, measured in the tens of billions of dollars, places Merck among the larger global pharmaceutical companies, and its liquidity on the NYSE supports active trading and positioning by long term and tactical investors alike.

Merck & Co. key data

• Company: Merck & Co., Inc.
• ISIN: US58933Y1055
• Ticker: NYSE: MRK
• Trading venue: NYSE
• Price (as of 16 May 2025, 16:00 EST): 112.50 USD
• Market capitalization: 284,000,000,000 USD (as of 16 May 2025)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500
• Next earnings date: 26 July 2025